Kezar Life Sciences is a clinical stage company developing novel small molecule therapeutics to treat autoimmune disorders and malignant diseases. Kezar's lead drug candidate, KZR‐616, leverages more than a decade of research directed by co‐founder Christopher Kirk into the unique role of the immunoproteasome in immune cell biology. In addition, Kezar is pursuing drug discovery programs targeting protein secretion and transmembrane protein expression that include a structured research collaboration with UC San Francisco.

Kezar completed a successful IPO in June 2018.